Recipharm Builds Global Scale With Kemwell Buy
This article was originally published in Scrip
Executive Summary
Recipharm AB is acquiring Kemwell's pharmaceutical contract development and manufacturing (CDMO) businesses for about SEK1.7bn ($206m) – a transaction that will give the Swedish firm an operational presence in the US and also builds on its position in emerging markets.